Dapsone as a cheap and safe second-line drug for chronic immune thrombocytopenia in developing countries: A prospective cohort study
Objective: The aim was to evaluate the efficacy and safety profile of dapsone as a cheap second-line treatment for chronic immune thrombocytopenia (ITP) in developing countries. Materials and Methods: A prospective study on 100 chronic ITP patients. These patients were put on dapsone after ruling ou...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2014-01-01
|
| Series: | Journal of Applied Hematology |
| Subjects: | |
| Online Access: | http://www.jahjournal.org/article.asp?issn=1658-5127;year=2014;volume=5;issue=3;spage=86;epage=90;aulast=Khan |
| _version_ | 1818847740766978048 |
|---|---|
| author | Yasir Bashir Khan Asif Ahmed Syed Sajad Geelani Shabeer Ahmad Mir Javid Rasool Bhat Nusrat Bashir Javeed Iqbal Bhat |
| author_facet | Yasir Bashir Khan Asif Ahmed Syed Sajad Geelani Shabeer Ahmad Mir Javid Rasool Bhat Nusrat Bashir Javeed Iqbal Bhat |
| author_sort | Yasir Bashir Khan |
| collection | DOAJ |
| description | Objective: The aim was to evaluate the efficacy and safety profile of dapsone as a cheap second-line treatment for chronic immune thrombocytopenia (ITP) in developing countries. Materials and Methods: A prospective study on 100 chronic ITP patients. These patients were put on dapsone after ruling out glucose 6 phosphate dehydrogenase deficiency and secondary causes of ITP. Results: The basic work up for secondary causes of ITP was negative. All these patients had been treated with steroids in the past. Anti-D had been given acutely in 20 patients, and intravenous immunoglobulin G had been given in 10 patients. Vincristine had been given to 20 of these patients. Dapsone was started in these patients, and 44% patients showed a response to treatment. The mean time to onset of response was 21 days. Out of these 44 patients, 21 (47.7%) went into remission and had platelet count >100,000/μl at 2 years post tapering of the treatment. Remaining 23 patients were kept on low dose dapsone and maintained their platelet counts. Adverse drug reactions included mild skin eruptions in 5% of patients, pruritus in 10% of patients, dose-related hemolysis in 1% of patients, methemoglobinemia in 1% of patients and Stevens Johnson syndrome in 1% of patients. 56 patients were nonresponders to the available, affordable conventional medical treatment and were referred to the surgical department for splenectomy, with a cure rate of 86% postsurgery. Conclusions: Dapsone is a safe, cheap and effective treatment option for patients with chronic ITP, who cannot afford the usual costlier second-line drugs. |
| first_indexed | 2024-12-19T06:06:15Z |
| format | Article |
| id | doaj.art-0ed98afefd414ba28deea2d763a71539 |
| institution | Directory Open Access Journal |
| issn | 1658-5127 |
| language | English |
| last_indexed | 2024-12-19T06:06:15Z |
| publishDate | 2014-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Applied Hematology |
| spelling | doaj.art-0ed98afefd414ba28deea2d763a715392022-12-21T20:33:08ZengWolters Kluwer Medknow PublicationsJournal of Applied Hematology1658-51272014-01-0153869010.4103/1658-5127.141991Dapsone as a cheap and safe second-line drug for chronic immune thrombocytopenia in developing countries: A prospective cohort studyYasir Bashir KhanAsif AhmedSyed Sajad GeelaniShabeer Ahmad MirJavid Rasool BhatNusrat BashirJaveed Iqbal BhatObjective: The aim was to evaluate the efficacy and safety profile of dapsone as a cheap second-line treatment for chronic immune thrombocytopenia (ITP) in developing countries. Materials and Methods: A prospective study on 100 chronic ITP patients. These patients were put on dapsone after ruling out glucose 6 phosphate dehydrogenase deficiency and secondary causes of ITP. Results: The basic work up for secondary causes of ITP was negative. All these patients had been treated with steroids in the past. Anti-D had been given acutely in 20 patients, and intravenous immunoglobulin G had been given in 10 patients. Vincristine had been given to 20 of these patients. Dapsone was started in these patients, and 44% patients showed a response to treatment. The mean time to onset of response was 21 days. Out of these 44 patients, 21 (47.7%) went into remission and had platelet count >100,000/μl at 2 years post tapering of the treatment. Remaining 23 patients were kept on low dose dapsone and maintained their platelet counts. Adverse drug reactions included mild skin eruptions in 5% of patients, pruritus in 10% of patients, dose-related hemolysis in 1% of patients, methemoglobinemia in 1% of patients and Stevens Johnson syndrome in 1% of patients. 56 patients were nonresponders to the available, affordable conventional medical treatment and were referred to the surgical department for splenectomy, with a cure rate of 86% postsurgery. Conclusions: Dapsone is a safe, cheap and effective treatment option for patients with chronic ITP, who cannot afford the usual costlier second-line drugs.http://www.jahjournal.org/article.asp?issn=1658-5127;year=2014;volume=5;issue=3;spage=86;epage=90;aulast=KhanDapsoneimmune thrombocytopeniatreatment |
| spellingShingle | Yasir Bashir Khan Asif Ahmed Syed Sajad Geelani Shabeer Ahmad Mir Javid Rasool Bhat Nusrat Bashir Javeed Iqbal Bhat Dapsone as a cheap and safe second-line drug for chronic immune thrombocytopenia in developing countries: A prospective cohort study Journal of Applied Hematology Dapsone immune thrombocytopenia treatment |
| title | Dapsone as a cheap and safe second-line drug for chronic immune thrombocytopenia in developing countries: A prospective cohort study |
| title_full | Dapsone as a cheap and safe second-line drug for chronic immune thrombocytopenia in developing countries: A prospective cohort study |
| title_fullStr | Dapsone as a cheap and safe second-line drug for chronic immune thrombocytopenia in developing countries: A prospective cohort study |
| title_full_unstemmed | Dapsone as a cheap and safe second-line drug for chronic immune thrombocytopenia in developing countries: A prospective cohort study |
| title_short | Dapsone as a cheap and safe second-line drug for chronic immune thrombocytopenia in developing countries: A prospective cohort study |
| title_sort | dapsone as a cheap and safe second line drug for chronic immune thrombocytopenia in developing countries a prospective cohort study |
| topic | Dapsone immune thrombocytopenia treatment |
| url | http://www.jahjournal.org/article.asp?issn=1658-5127;year=2014;volume=5;issue=3;spage=86;epage=90;aulast=Khan |
| work_keys_str_mv | AT yasirbashirkhan dapsoneasacheapandsafesecondlinedrugforchronicimmunethrombocytopeniaindevelopingcountriesaprospectivecohortstudy AT asifahmed dapsoneasacheapandsafesecondlinedrugforchronicimmunethrombocytopeniaindevelopingcountriesaprospectivecohortstudy AT syedsajadgeelani dapsoneasacheapandsafesecondlinedrugforchronicimmunethrombocytopeniaindevelopingcountriesaprospectivecohortstudy AT shabeerahmadmir dapsoneasacheapandsafesecondlinedrugforchronicimmunethrombocytopeniaindevelopingcountriesaprospectivecohortstudy AT javidrasoolbhat dapsoneasacheapandsafesecondlinedrugforchronicimmunethrombocytopeniaindevelopingcountriesaprospectivecohortstudy AT nusratbashir dapsoneasacheapandsafesecondlinedrugforchronicimmunethrombocytopeniaindevelopingcountriesaprospectivecohortstudy AT javeediqbalbhat dapsoneasacheapandsafesecondlinedrugforchronicimmunethrombocytopeniaindevelopingcountriesaprospectivecohortstudy |